Malaysia was BioNexus Gene Lab’s largest region in fiscal 2025, bringing in $5.83M of $7.42M (79%).
| Geography | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Malaysia | $8.22M | $7.46M | $5.83M |
| Maldives | $637.19K | $762.14K | $680.99K |
| Sri Lanka | $87.03K | $459.00K | $452.64K |
| Singapore | $244.40K | $572.03K | $240.76K |
| Indonesia | — | $138.30K | $114.87K |
| Bangladesh | $538.06K | $123.27K | $106.25K |
| Nigeria | $42.07K | — | — |
| Total | $9.77M | $9.51M | $7.42M |
BioNexus Gene Lab brought in $7.42M from its six regions in fiscal 2025, the year ended December 31, 2025. That was down 21.9% from $9.51M in fiscal 2024. Malaysia was the largest at $5.83M (78.5%), ahead of Maldives at $680.99K (9.2%) and Sri Lanka at $452.64K (6.1%). The other three regions brought in $461.88K combined.
Compared with fiscal 2024, every region above 2% of revenue shrank. Sri Lanka held up best, down 1.4% to $452.64K, and Singapore fell the most, down 57.9% to $240.76K.
BioNexus Gene Lab began breaking out Indonesia in fiscal 2024, when it brought in $138.30K. BioNexus Gene Lab stopped reporting Nigeria as a separate region after fiscal 2023, when it brought in $42.07K.
Trading Of Industrial Chemicals was BioNexus Gene Lab’s largest revenue line in fiscal 2025, bringing in $7.41M of $7.44M (99%).
| Timing of Transfer of Good or Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Trading Of Industrial Chemicals | $9.75M | $9.49M | $7.41M |
| Screening Services & Related Sales | $24.22K | $16.07K | $19.09K |
| Provision For Genomic Screening Services | — | $16.07K | $19.09K |
| Total | $9.77M | $9.53M | $7.44M |
BioNexus Gene Lab brought in $7.44M from its three revenue lines in fiscal 2025, the year ended December 31, 2025. That was down 21.9% from $9.53M in fiscal 2024. Trading Of Industrial Chemicals was the largest at $7.41M (99.5%), ahead of Screening Services & Related Sales at $19.09K (0.3%) and Provision For Genomic Screening Services at $19.09K (0.3%).
BioNexus Gene Lab began breaking out Provision For Genomic Screening Services in fiscal 2024, when it brought in $16.07K.
Chemrex was BioNexus Gene Lab’s largest revenue line in fiscal 2022, bringing in $10.83M of $10.93M (99%).
| Related Party Transaction | FY 2020 | FY 2021 | FY 2022 |
|---|---|---|---|
| Chemrex | $11.26M | $11.85M | $10.83M |
| Bionexus Malaysia | $134.10K | $1.52M | — |
| Mrna Scientific Malaysia | — | — | $95.82K |
| Total | $11.39M | $13.36M | $10.93M |
BioNexus Gene Lab brought in $10.93M from its two revenue lines in fiscal 2022, the year ended December 31, 2022. BioNexus Gene Lab regrouped these revenue lines after fiscal 2021, so the total does not compare directly with that year's $13.36M. Chemrex was the largest at $10.83M (99.1%), ahead of Mrna Scientific Malaysia at $95.82K (0.9%).
BioNexus Gene Lab began breaking out Mrna Scientific Malaysia in fiscal 2022, when it brought in $95.82K. BioNexus Gene Lab stopped reporting Bionexus Malaysia as a separate revenue line after fiscal 2021, when it brought in $1.52M.
BioNexus Gene Lab (BGLC) reports its revenue by geography, by timing of transfer of good or service and by related party transaction. In fiscal 2025, Malaysia was its largest region, bringing in $5.83M (78.5% of the total), followed by Maldives at $680.99K (9.2%).
Malaysia was BioNexus Gene Lab's largest region in fiscal 2025, bringing in $5.83M, or 78.5% of the $7.42M total across its six regions.
Trading Of Industrial Chemicals was BioNexus Gene Lab's largest revenue line in fiscal 2025, bringing in $7.41M, or 99.5% of the $7.44M total across its three revenue lines.
Every figure comes from BioNexus Gene Lab's annual financial filings, as reported. Each line keeps the name BioNexus Gene Lab gives it, and years follow its fiscal calendar.
BioNexus Gene Lab's revenue by geography goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.